Drug could help treat rare form of lung cancer
A new drug could help people with a rare form of long cancer.
The drug from Pfizer helped 60% of patients taking part in a clinical trial live five years without their cancer progressing. That's years longer than other drugs, according to a study published in the Journal of Clinical Oncology.
A new drug could help people with a rare form of lung cancer.
The drug from Pfizer helped 60% of patients taking part in a clinical trial live five years without their cancer progressing. That’s years longer than other drugs, according to a study published in the Journal of Clinical Oncology.
The drug treats what is called ALK positive lung cancers, which tend to happen in younger patients who do not smoke.
It’s effective at stopping the cancer from spreading to the brain, the study found.